Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Gianluca Curti

Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U-300 and Glargine U-100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes

Diabetes Care

English

Related publications

Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL in the Treatment of Diabetes and Their Clinical Relevance

Expert Opinion on Drug Metabolism and Toxicology

English

Pdb86 - Cost-Utility Analysis of Insulin Glargine 300 U/Ml Versus Insulin Glargine 100 U/Ml and Insulin Degludec 100 U/Ml in Patients With Type 2 Diabetes Mellitus in Bulgaria

English

Pdb79 - Cost-Utility Analysis of Insulin Glargine 300 U/Ml Versus Insulin Glargine 100 U/Ml and Insulin Degludec 100 U/Ml in Patients With Type 2 Diabetes Mellitus in Croatia

English

Continuous Glucose Monitoring During Basal–Bolus Therapy Using Insulin Glargine 300 U mL−1 and Glargine 100 U mL−1 in Japanese People With Type 1 Diabetes Mellitus: A Crossover Pilot Study

English

In Silico Head-To-Head Comparison of Insulin Glargine 300 U/Ml and Insulin Degludec 100 U/Ml in Type 1 Diabetes

Diabetes Technology and Therapeutics

Medicine

Endocrinology

Medical Laboratory Technology

Metabolism

Diabetes

2020

English

InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons With Type 1 Diabetes Using Continuous Glucose Monitoring—Study Design

English

Glycaemic Control, Hypoglycaemia, and Weight Change With Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Japanese Adults With Type 2 Diabetes: A 12-Month Comparison by Concomitant Sulphonylurea and/or Glinide Use

Diabetes, Obesity and Metabolism

English

New Insulin Glargine 300 Units{middle Dot}mL-1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units{middle Dot}mL-1

English

Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People With Type 2 Diabetes

Diabetes Technology and Therapeutics

Medicine

Endocrinology

Medical Laboratory Technology

Metabolism

Diabetes

2016

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Gianluca Curti

Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U-300 and Glargine U-100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes

Related publications

Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL in the Treatment of Diabetes and Their Clinical Relevance

Pdb86 - Cost-Utility Analysis of Insulin Glargine 300 U/Ml Versus Insulin Glargine 100 U/Ml and Insulin Degludec 100 U/Ml in Patients With Type 2 Diabetes Mellitus in Bulgaria

Pdb79 - Cost-Utility Analysis of Insulin Glargine 300 U/Ml Versus Insulin Glargine 100 U/Ml and Insulin Degludec 100 U/Ml in Patients With Type 2 Diabetes Mellitus in Croatia

Continuous Glucose Monitoring During Basal–Bolus Therapy Using Insulin Glargine 300 U mL−1 and Glargine 100 U mL−1 in Japanese People With Type 1 Diabetes Mellitus: A Crossover Pilot Study

In Silico Head-To-Head Comparison of Insulin Glargine 300 U/Ml and Insulin Degludec 100 U/Ml in Type 1 Diabetes

InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons With Type 1 Diabetes Using Continuous Glucose Monitoring—Study Design

Glycaemic Control, Hypoglycaemia, and Weight Change With Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Japanese Adults With Type 2 Diabetes: A 12-Month Comparison by Concomitant Sulphonylurea and/or Glinide Use

New Insulin Glargine 300 Units{middle Dot}mL-1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units{middle Dot}mL-1

Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People With Type 2 Diabetes